Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Writes for:

Latest From Andrew McConaghie

How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Commercial Companies

Is Biogen’s Aducanumab Approvable? Opinions Divided Ahead Of Review

Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but  US FDA could offer it the benefit of the doubt.

Commercial Companies

Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval

Timing means full EU approval could coincide with US FDA authorization later this year.

Commercial Companies

Vertex Suffers Setback In Its Search For Post-CF Blockbusters

Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.

Commercial Clinical Trials

Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off

Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.

Clinical Trials Commercial

UK Biotech Defies Pandemic, On Course For Record Fundraising Year

The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.

Commercial Companies
See All
UsernamePublicRestriction

Register